It sounds like the question might be about the GDNF trial results for Parkinson's disease treatment — a small but exciting British clinical trial involving 41 patients that explored whether "growth factor" proteins could restore damaged brain cells.
Here's a summary of what the trial found:
- At 9 months, there were no Show Full Answer
It sounds like the question might be about the GDNF trial results for Parkinson's disease treatment — a small but exciting British clinical trial involving 41 patients that explored whether "growth factor" proteins could restore damaged brain cells.
Here's a summary of what the trial found:
- At 9 months, there were no significant differences in Parkinson's symptoms between those who received GDNF and those who didn't
- However, brain scans showed a 100% improvement in a key brain area, suggesting damaged dopamine-producing cells were being "reawakened"
- At 18 months, when all participants had received GDNF, both groups showed moderate to large improvements in symptoms
The results are promising but come with some important cautions:
- The trial was very small (only 41 patients)
- At the 18-month mark, the trial was no longer "blinded," making it harder to rule out a placebo effect
- Researchers suggest a longer, larger trial with possibly higher doses may produce clearer results
Researchers remain cautiously optimistic. The brain scan improvements were described as "beyond anything seen previously" in similar trials. It's still early days, but GDNF continues to hold real potential for people living with Parkinson's.
May 14
Join
Your Privacy Choices
